Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 August 2005, Vol. 106, No. 3, pp. 841-851.
Prepublished online as a Blood First Edition Paper on April 12, 2005; DOI 10.1182/blood-2004-05-2017.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-05-2017v1
106/3/841    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sloand, E. M
Right arrow Articles by Young, N. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sloand, E. M
Right arrow Articles by Young, N. S
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted June 3, 2004
Accepted March 10, 2005

Preferential suppression of trisomy 8 versus normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome

Elaine M Sloand*, Lori Mainwaring, Monika Fuhrer, Shakti Ramkissoon, Antonio M Risitano, Keyvan Keyvanafar, Jun Lu, Atanu Basu, A J Barrett, and Neal S Young

Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA

* Corresponding author; email: sloande{at}nih.gov.

Clinical observations and experimental evidence link bone marrow failure in myelodysplastic syndrome (MDS) with a T cell-dominated autoimmune process. Immunosuppressive therapy is effective in improving cytopenias in selected cases. Trisomy 8 is a frequent cytogenetic abnormality present in bone marrow cells in patients with MDS and its presence has anecdotally been associated with good response to immunotherapy. We studied 34 patients with trisomy 8 in bone marrow cells, some of whom were undergoing treatment with antithymocyte globulin (ATG). All had significant CD8+ T cell expansions of one or more TCR V{beta} subfamilies as measured by flow cytometry; expanded subfamilies showed CDR3 skewing by spectratyping. Sorted T cells of the expanded V{beta} subfamilies, but not of the remaining subfamilies, inhibited proliferation of trisomy 8 cells in short-term culture. The negative effects of V{beta}-expanded T cells were inhibited by MHC class I monoclonal antibody (mAb) and Fas antagonist and required direct cell-to-cell contact. Sixty-seven percent of de novo MDS patients with trisomy 8 as the sole karyotypic abnormality responded to ATG with durable reversal of cytopenias and restoration of transfusion-independence, with stable increase in the proportion of trisomy 8 bone marrow cells and normalization of the T cell repertoire. Increased T cells with apparent specificity for trisomy 8 cells are consistent with an autoimmune pathophysiology in trisomy 8 MDS.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
S. Y. Kordasti, W. Ingram, J. Hayden, D. Darling, L. Barber, B. Afzali, G. Lombardi, M. W. Wlodarski, J. P. Maciejewski, F. Farzaneh, et al.
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Blood, August 1, 2007; 110(3): 847 - 850.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. M. Sloand, L. Pfannes, G. Chen, S. Shah, E. E. Solomou, J. Barrett, and N. S. Young
CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins
Blood, March 15, 2007; 109(6): 2399 - 2405.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
E. M. Sloand, K. Rezvani, A. Yong, D. Douek, R. Kurlander, D. Price, J. Barrett, and N. S. Young
Cytotoxic CD8 T Cell Immune Responses to Wilms Tumor Protein (WT-1) Characterizes Immunosuppression-Responsive Myelodysplasia (MDS).
Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 849 - 849.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. S. Young, R. T. Calado, and P. Scheinberg
Current concepts in the pathophysiology and treatment of aplastic anemia
Blood, October 15, 2006; 108(8): 2509 - 2519.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Ogata, Y. Kishikawa, C. Satoh, H. Tamura, K. Dan, and A. Hayashi
Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes
Blood, August 1, 2006; 108(3): 1037 - 1044.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Braun, G. Carvalho, A. Coquelle, M.-C. Vozenin, P. Lepelley, F. Hirsch, J.-J. Kiladjian, V. Ribrag, P. Fenaux, and G. Kroemer
NF-{kappa}B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome
Blood, February 1, 2006; 107(3): 1156 - 1165.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
N. S. Young
Pathophysiologic Mechanisms in Acquired Aplastic Anemia
Hematology, January 1, 2006; 2006(1): 72 - 77.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020